MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial

Patrick J. Bolan, Eunhee Kim, Benjamin A. Herman, Gillian M. Newstead, Mark A. Rosen, Mitchell D. Schnall, Etta D. Pisano, Paul T. Weatherall, Elizabeth A. Morris, Constance D. Lehman, Michael Garwood, Michael T. Nelson, Douglas Yee, Sandra M. Polin, Laura J. Esserman, Constantine A. Gatsonis, Gregory J. Metzger, David C. Newitt, Savannah C. Partridge, Nola M. Hylton

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment. Materials and Methods: This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models. Results: Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC=0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC=0.51, 95% CI: 0.27-0.75). Conclusion: The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.

Original languageEnglish (US)
JournalJournal of Magnetic Resonance Imaging
DOIs
StateAccepted/In press - 2016

Fingerprint

Magnetic Resonance Spectroscopy
Breast Neoplasms
Area Under Curve
Drug Therapy
Logistic Models
Confidence Intervals
Health Insurance Portability and Accountability Act
Therapeutics
Research Ethics Committees
Choline
Radiology
ROC Curve
Clinical Trials

Keywords

  • Breast cancer
  • Choline
  • Magnetic resonance spectroscopy
  • Treatment response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Bolan, P. J., Kim, E., Herman, B. A., Newstead, G. M., Rosen, M. A., Schnall, M. D., ... Hylton, N. M. (Accepted/In press). MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.25560

MR spectroscopy of breast cancer for assessing early treatment response : Results from the ACRIN 6657 MRS trial. / Bolan, Patrick J.; Kim, Eunhee; Herman, Benjamin A.; Newstead, Gillian M.; Rosen, Mark A.; Schnall, Mitchell D.; Pisano, Etta D.; Weatherall, Paul T.; Morris, Elizabeth A.; Lehman, Constance D.; Garwood, Michael; Nelson, Michael T.; Yee, Douglas; Polin, Sandra M.; Esserman, Laura J.; Gatsonis, Constantine A.; Metzger, Gregory J.; Newitt, David C.; Partridge, Savannah C.; Hylton, Nola M.

In: Journal of Magnetic Resonance Imaging, 2016.

Research output: Contribution to journalArticle

Bolan, PJ, Kim, E, Herman, BA, Newstead, GM, Rosen, MA, Schnall, MD, Pisano, ED, Weatherall, PT, Morris, EA, Lehman, CD, Garwood, M, Nelson, MT, Yee, D, Polin, SM, Esserman, LJ, Gatsonis, CA, Metzger, GJ, Newitt, DC, Partridge, SC & Hylton, NM 2016, 'MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial', Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.25560
Bolan, Patrick J. ; Kim, Eunhee ; Herman, Benjamin A. ; Newstead, Gillian M. ; Rosen, Mark A. ; Schnall, Mitchell D. ; Pisano, Etta D. ; Weatherall, Paul T. ; Morris, Elizabeth A. ; Lehman, Constance D. ; Garwood, Michael ; Nelson, Michael T. ; Yee, Douglas ; Polin, Sandra M. ; Esserman, Laura J. ; Gatsonis, Constantine A. ; Metzger, Gregory J. ; Newitt, David C. ; Partridge, Savannah C. ; Hylton, Nola M. / MR spectroscopy of breast cancer for assessing early treatment response : Results from the ACRIN 6657 MRS trial. In: Journal of Magnetic Resonance Imaging. 2016.
@article{5e249fd339214f88ac875641fd6f68f3,
title = "MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial",
abstract = "Purpose: To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment. Materials and Methods: This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models. Results: Of the 119 subjects enrolled, only 29 cases (24{\%}) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC=0.53, 95{\%} confidence interval [CI]: 0.27-0.79) or radiologic response (AUC=0.51, 95{\%} CI: 0.27-0.75). Conclusion: The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.",
keywords = "Breast cancer, Choline, Magnetic resonance spectroscopy, Treatment response",
author = "Bolan, {Patrick J.} and Eunhee Kim and Herman, {Benjamin A.} and Newstead, {Gillian M.} and Rosen, {Mark A.} and Schnall, {Mitchell D.} and Pisano, {Etta D.} and Weatherall, {Paul T.} and Morris, {Elizabeth A.} and Lehman, {Constance D.} and Michael Garwood and Nelson, {Michael T.} and Douglas Yee and Polin, {Sandra M.} and Esserman, {Laura J.} and Gatsonis, {Constantine A.} and Metzger, {Gregory J.} and Newitt, {David C.} and Partridge, {Savannah C.} and Hylton, {Nola M.}",
year = "2016",
doi = "10.1002/jmri.25560",
language = "English (US)",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - MR spectroscopy of breast cancer for assessing early treatment response

T2 - Results from the ACRIN 6657 MRS trial

AU - Bolan, Patrick J.

AU - Kim, Eunhee

AU - Herman, Benjamin A.

AU - Newstead, Gillian M.

AU - Rosen, Mark A.

AU - Schnall, Mitchell D.

AU - Pisano, Etta D.

AU - Weatherall, Paul T.

AU - Morris, Elizabeth A.

AU - Lehman, Constance D.

AU - Garwood, Michael

AU - Nelson, Michael T.

AU - Yee, Douglas

AU - Polin, Sandra M.

AU - Esserman, Laura J.

AU - Gatsonis, Constantine A.

AU - Metzger, Gregory J.

AU - Newitt, David C.

AU - Partridge, Savannah C.

AU - Hylton, Nola M.

PY - 2016

Y1 - 2016

N2 - Purpose: To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment. Materials and Methods: This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models. Results: Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC=0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC=0.51, 95% CI: 0.27-0.75). Conclusion: The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.

AB - Purpose: To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment. Materials and Methods: This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models. Results: Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC=0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC=0.51, 95% CI: 0.27-0.75). Conclusion: The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.

KW - Breast cancer

KW - Choline

KW - Magnetic resonance spectroscopy

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=85006913843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006913843&partnerID=8YFLogxK

U2 - 10.1002/jmri.25560

DO - 10.1002/jmri.25560

M3 - Article

C2 - 27981651

AN - SCOPUS:85006913843

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

ER -